Aurion Biotech

Aurion Biotech is a clinical-stage biotechnology company focused on developing regenerative therapies to restore vision for patients with corneal endothelial diseases. Headquartered in Seattle, WA, with additional offices in Cambridge, MA, and Tokyo, Japan, the company leverages advanced cell therapies to address vision loss. The company's primary product is an allogeneic cell therapy for corneal endothelial diseases, commercially launched in Japan as Vyznova in September 2024. Aurion Biotech is also developing AURN001, an improved formulation of Vyznova, which aims to enhance manufacturing scalability and shelf life. The company has received significant funding, including a $120 million Series C financing round, and has been recognized for its innovative approach, earning a spot on Fast Company’s Annual List of World’s Most Innovative Companies of 2025. Aurion Biotech plans to advance AURN001 into Phase 3 clinical trials in late 2025, continuing its mission to provide effective therapies for vision restoration.